22 Jul Kytopen
Bethany Grant, Chief Technology Officer
Kytopen, a spin-out of MIT, is a transformative biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development, and manufacturing phases of cell engineering. Flowfect®, a gentle, non-viral delivery method, unlocks new therapeutic approaches by engineering immune cells with minimal disruption, preserving the functionality and viability of human cells. Flowfect® accelerates therapies from the bench to clinical applications through flexibility and scalability, which drives higher cell yields, faster approvals, and better outcomes from potentially curative cell-based treatments. Kytopen’s goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to increase access to more patients. Our initial offering, Flowfect®Tx, will be going to market later this year.